Revelation Biosciences, Inc.

REVB

NASDAQ

Healthcare

Biotechnology

San Diego, CA, US8 employeesrevbiosciences.com

$1.22

-0.01(-0.80%)

Mkt Cap $2M

$1.12

$44.28

52-Week Range

At a Glance

AI-generated

8-K

Revelation Biosciences, Inc. held a Special Meeting on March 18, 2026, where stockholders approved the issuance of common stock pursuant to Class J Common Stock Warrants to exceed the Nasdaq Exchange Cap of 20% of outstanding shares. This approval sets the warrants' expiration date to March 18, 2031, enabling potential exercises without further stockholder consent.

$2M

Market Cap

—

Revenue

-$2M

Net Income

Employees8

Fundamentals

How The Business Makes Money

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Industry Biotechnology

Activity

What Changed Recently

Securities Modification

Mar 18, 2026

Material Modification to Rights of Security Holders. Under Nasdaq rules, a listed company may not issue shares at a price below market value in an amount exceed

Financial Results

Feb 25, 2026

and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or ot

Material Agreement

Jan 28, 2026

of this Form 8-K is incorporated herein by reference. The form of the Class J Common Stock Warrants are filed as Exhibit 4.1 to this Form 8-K and is incorporate

Other Event

Jan 21, 2026

and in Exhibit 99.1 and 99.2 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o

Peer Companies

Company	Price	Change	Market Cap	P/E
ONCOOnconetix, Inc.	$1.48	-21.08%	$5M	-0.0
SLRXSLRX	$0.84	+29.23%	$5M	—
GTBPGT Biopharma, Inc.	$0.44	+7.01%	$5M	-0.1
INDPIndaptus Therapeutics, In...	$1.57	-7.35%	$3M	-0.2
AZTRAzitra, Inc.	$0.23	-4.21%	$2M	—
SLXNSilexion Therapeutics Ltd...	$1.18	-3.28%	$661.9K	-0.3
ATXIAvenue Therapeutics, Inc.	$0.16	-40.72%	$523.7K	-0.2
SPRCSciSparc Ltd.	$3.56	-2.73%	$205.9K	-0.0

Analyst View

Company Profile

CIK0001810560

ISINUS76135L8046

CUSIP76135L804

Phone650 800 3717

Address4660 La Jolla Village Drive, San Diego, CA, 92122, US

SEC EDGAR